Takeover Tango: Healthcare's Best Dance Partner Is...

AbbVie and Shire. Valeant and Allergan. The drugmaker deal dances are underway -- but it takes two to tango.

Jun 24, 2014 at 5:00PM

Buying a drug company ain't what it used to be.

Once upon a time, a larger pharmaceutical firm would make an offer for a smaller company. Said smaller drugmaker would swoon at the immediate gains for its shareholders. The deal would go through -- and everyone lived happily ever after. At least, that's how the story frequently unfolded.

Now, though, parties involved in a potential merger or acquisition are likely to perform a delicate dance back and forth for all the world to see. Sometimes, this results in a match made in heaven. And sometimes one company is left standing alone on the dance floor. AbbVie (NYSE:ABBV) and Valeant Pharmaceuticals (NYSE:VRX) are the latest waiting to see how their drugmaker deal dances will end.

The fleeing foxtrot
AbbVie recently discovered that the third time isn't always the charm. Shire Plc (NASDAQ:SHPG) rebuffed last week's acquisition offer by AbbVie -- just as it did two earlier attempts. The Dublin, Ireland-based firm thinks remaining solo will provide shareholders more value.

In an interview with The Wall Street Journal on Monday, Shire CEO Flemming Ornskov predicted that revenue will double by 2020 to $10 billion. Ornskov says that 30% of that revenue will stem from drugs currently in Shire's pipeline. If he's right, the $46.5 billion offer by AbbVie isn't high enough.

That kind of growth surely interests AbbVie, which receives the bulk of its sales from a single drug: Humira. Perhaps just as enticing, though, is the prospect of reducing its corporate taxes by taking advantage of Shire's Irish domicile. It takes two to tango, though. At this point, it looks like AbbVie's bid will have to increase significantly for Shire to be wooed successfully. 

The slideshow salsa
Allergan (NYSE:AGN) stands out as another reluctant dance partner. Valeant mounted a hostile acquisition attempt last week. Of course, this story is pretty well-known by now, as Valeant and investor William Ackman's Pershing Square Capital Management combining in April to make a play for Allergan.

This pharmaceutical promenade featured a slideshow battle. A couple of weeks ago, Allergan released a presentation highlighting the reasons why a deal with Valeant didn't make sense. One key argument contrasted the "strong, long-term organic growth" of Allergan with the "anemic growth" powered largely by "unsustainable price increases." 

Valeant fired back on Monday with a point-by-point rebuttal of Allergan's slideshow. In response to the allegation of anemic growth, Valeant stated that it has "averaged ~7% pro forma organic growth since 2010" with 13 of its top 15 products experiencing growth -- nine of which are seeing volume growth.  

Judging the dancers
Are these companies ready to keep this going -- or will they just trip? It's not difficult to see why AbbVie and Valeant have their sights set on Shire and Allergan, respectively. But the best dancer award out of these four organizations should go to Shire.

AbbVie's offer for Shire helped jump-start the Irish pharmaceutical firm's stock. Shire's decision to resist the temptation to sell appears to be the right move. Even if projections of a doubling of sales by 2020 proves overly optimistic, shareholders should be able to fetch a better price in the future than AbbVie's previous offers. The truth is that AbbVie needs Shire more than Shire needs AbbVie.

Rumors have also floated that Allergan could make a bid for Shire to thwart a hostile takeover by Valeant. While such an offer hasn't materialized yet, it underscores the attractiveness of the Irish drugmaker. Who will end up scooping up Shire, if anyone, remains to be seen. I don't think we've seen the high mark for the stock yet, though. For now, the dance goes on. 

Dividend stocks that will have you dancing
The smartest investors know that dividend stocks simply crush their non-dividend paying counterparts over the long term. That's beyond dispute. They also know that a well-constructed dividend portfolio creates wealth steadily, while still allowing you to sleep like a baby. Knowing how valuable such a portfolio might be, our top analysts put together a report on a group of high-yielding stocks that should be in any income investor's portfolio. To see our free report on these stocks, just click here now.

 

Keith Speights has no position in any stocks mentioned. The Motley Fool recommends Valeant Pharmaceuticals. The Motley Fool owns shares of Valeant Pharmaceuticals. Try any of our Foolish newsletter services free for 30 days. We Fools may not all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy.

1 Key Step to Get Rich

Our mission at The Motley Fool is to help the world invest better. Whether that’s helping people overcome their fear of stocks all the way to offering clear and successful guidance on complicated-sounding options trades, we can help.

Feb 1, 2016 at 4:54PM

To be perfectly clear, this is not a get-rich action that my Foolish colleagues and I came up with. But we wouldn't argue with the approach.

A 2015 Business Insider article titled, "11 websites to bookmark if you want to get rich" rated The Motley Fool as the #1 place online to get smarter about investing.

"The Motley Fool aims to build a strong investment community, which it does by providing a variety of resources: the website, books, a newspaper column, a radio [show], and [newsletters]," wrote (the clearly insightful and talented) money reporter Kathleen Elkins. "This site has something for every type of investor, from basic lessons for beginners to investing commentary on mutual funds, stock sectors, and value for the more advanced."

Our mission at The Motley Fool is to help the world invest better, so it's nice to receive that kind of recognition. It lets us know we're doing our job.

Whether that's helping the entirely uninitiated overcome their fear of stocks all the way to offering clear and successful guidance on complicated-sounding options trades, we want to provide our readers with a boost to the next step on their journey to financial independence.

Articles and beyond

As Business Insider wrote, there are a number of resources available from the Fool for investors of all levels and styles.

In addition to the dozens of free articles we publish every day on our website, I want to highlight two must-see spots in your tour of fool.com.

For the beginning investor

Investing can seem like a Big Deal to those who have yet to buy their first stock. Many investment professionals try to infuse the conversation with jargon in order to deter individual investors from tackling it on their own (and to justify their often sky-high fees).

But the individual investor can beat the market. The real secret to investing is that it doesn't take tons of money, endless hours, or super-secret formulas that only experts possess.

That's why we created a best-selling guide that walks investors-to-be through everything they need to know to get started. And because we're so dedicated to our mission, we've made that available for free.

If you're just starting out (or want to help out someone who is), go to www.fool.com/beginners, drop in your email address, and you'll be able to instantly access the quick-read guide ... for free.

For the listener

Whether it's on the stationary exercise bike or during my daily commute, I spend a lot of time going nowhere. But I've found a way to make that time benefit me.

The Motley Fool offers five podcasts that I refer to as "binge-worthy financial information."

Motley Fool Money features a team of our analysts discussing the week's top business and investing stories, interviews, and an inside look at the stocks on our radar. It's also featured on several dozen radio stations across the country.

The hosts of Motley Fool Answers challenge the conventional wisdom on life's biggest financial issues to reveal what you really need to know to make smart money moves.

David Gardner, co-founder of The Motley Fool, is among the most respected and trusted sources on investing. And he's the host of Rule Breaker Investing, in which he shares his insights into today's most innovative and disruptive companies ... and how to profit from them.

Market Foolery is our daily look at stocks in the news, as well as the top business and investing stories.

And Industry Focus offers a deeper dive into a specific industry and the stories making headlines. Healthcare, technology, energy, consumer goods, and other industries take turns in the spotlight.

They're all informative, entertaining, and eminently listenable ... and I don't say that simply because the hosts all sit within a Nerf-gun shot of my desk. Rule Breaker Investing and Answers contain timeless advice, so you might want to go back to the beginning with those. The other three take their cues from the market, so you'll want to listen to the most recent first. All are available at www.fool.com/podcasts.

But wait, there's more

The book and the podcasts – both free ... both awesome – also come with an ongoing benefit. If you download the book, or if you enter your email address in the magical box at the podcasts page, you'll get ongoing market coverage sent straight to your inbox.

Investor Insights is valuable and enjoyable coverage of everything from macroeconomic events to investing strategies to our analyst's travels around the world to find the next big thing. Also free.

Get the book. Listen to a podcast. Sign up for Investor Insights. I'm not saying that any of those things will make you rich ... but Business Insider seems to think so.


Compare Brokers